Presynaptic neurotoxins: An expanding array of natural and modified molecules

Cell Calcium

Volumn 52, Issue 3-4, 2012, Pages 234-240

  Davletov, Bazbek ^a   Ferrari, Enrico ^a   Ushkaryov, Yuri ^b  

^a MRC LABORATORY OF MOLECULAR BIOLOGY   (United Kingdom)

^b MEDWAY SCHOOL OF PHARMACY   (United Kingdom)

Author keywords

Black widow spider; Botulinum; Calcium; Chimera; Clostridial; Exocytosis; Latrotoxin; Neurotoxin; Neurotransmitter release; Presynaptic; SNARE proteins

Indexed keywords

ALPHA LATROTOXIN; BACTERIAL TOXIN; BOTULINUM TOXIN; BOTULINUM TOXIN A; BOTULINUM TOXIN B; BOTULINUM TOXIN D; BOTULINUM TOXIN E; BOTULINUM TOXIN F; BOTULINUM TOXIN G; CLOSTRIDIAL NEUROTOXIN; NEUROTOXIN; SNARE PROTEIN; SPIDER VENOM; TETANUS TOXIN; UNCLASSIFIED DRUG;

ARTICLE; CLOSTRIDIUM; EXOCYTOSIS; HUMAN; MUSCLE SPASM; NEUROTRANSMITTER RELEASE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; SYNAPTOSOME; TOXIN ANALYSIS; TOXIN STRUCTURE;

ANIMALIA; ARANEAE; ARTHROPODA; HARNESS; LATRODECTUS; VERTEBRATA;

EID: 84865767118     PISSN: 01434160     EISSN: 15321991     Source Type: Journal    
DOI: 10.1016/j.ceca.2012.05.006     Document Type: Article

References (86)

1. Sollner T., Whiteheart S.W., Brunner M., Erdjument-Bromage H., Geromanos S., Tempst P., Rothman J.E. SNAP receptors implicated in vesicle targeting and fusion. Nature 1993, 362:318-324.
2. Sutton R.B., Fasshauer D., Jahn R., Brunger A.T. Crystal structure of a SNARE complex involved in synaptic exocytosis at 2.4Å resolution. Nature 1998, 395:347-353.
3. Davletov B., Montecucco C. Lipid function at synapses. Current Opinion in Neurobiology 2010, 20:543-549.
4. Schiavo G., Matteoli M., Montecucco C. Neurotoxins affecting neuroexocytosis. Physiological Reviews 2000, 80:717-766.
5. Foster K.A. Engineered toxins: new therapeutics. Toxicon 2009, 54:587-592.
6. Pickett A., Perrow K. Towards new uses of botulinum toxin as a novel therapeutic tool. Toxins (Basel) 2011, 3:63-81.
7. Rossetto O., Seveso M., Caccin P., Schiavo G., Montecucco C. Tetanus and botulinum neurotoxins: turning bad guys into good by research. Toxicon 2001, 39:27-41.
8. Rossetto O., de Bernard M., Pellizzari R., Vitale G., Caccin P., Schiavo G., Montecucco C. Bacterial toxins with intracellular protease activity. Clinica Chimica Acta 2000, 291:189-199.
9. Schiavo G., Benfenati F., Poulain B., Rossetto O., Polverino de Laureto P., DasGupta B.R., Montecucco C. Tetanus and botulinum-B neurotoxins block neurotransmitter release by proteolytic cleavage of synaptobrevin. Nature 1992, 359:832-835.
10. Davletov B., Bajohrs M., Binz T. Beyond BOTOX: advantages and limitations of individual botulinum neurotoxins. Trends in Neurosciences 2005, 28:446-452.
11. Foran P.G., Davletov B., Meunier F.A. Getting muscles moving again after botulinum toxin: novel therapeutic challenges. Trends in Molecular Medicine 2003, 9:291-299.
12. Montal M. Botulinum neurotoxin: a marvel of protein design. Annual Review of Biochemistry 2010, 79:591-617.
13. Strotmeier J., Gu S., Jutzi S., Mahrhold S., Zhou J., Pich A., Eichner T., Bigalke H., Rummel A., Jin R., Binz T. The biological activity of botulinum neurotoxin type C is dependent upon novel types of ganglioside binding sites. Molecular Microbiology 2011, 81:143-156.
14. Schnaar R.L. Brain gangliosides in axon-myelin stability and axon regeneration. FEBS Letters 2010, 584:1741-1747.
15. Montecucco C., Schiavo G., Dasgupta B.R. Effect of pH on the interaction of botulinum neurotoxins A, B and E with liposomes. Biochemical Journal 1989, 259:47-53.
16. Fu Z., Chen C., Barbieri J.T., Kim J.J., Baldwin M.R. Glycosylated SV2 and gangliosides as dual receptors for botulinum neurotoxin serotype F. Biochemistry 2009, 48:5631-5641.
17. Dong M., Yeh F., Tepp W.H., Dean C., Johnson E.A., Janz R., Chapman E.R. SV2 is the protein receptor for botulinum neurotoxin A. Science 2006, 312:592-596.
18. Rummel A., Karnath T., Henke T., Bigalke H., Binz T. Synaptotagmins I and II act as nerve cell receptors for botulinum neurotoxin G. Journal of Biological Chemistry 2004, 279:30865-30870.
19. Lalli G., Bohnert S., Deinhardt K., Verastegui C., Schiavo G. The journey of tetanus and botulinum neurotoxins in neurons. Trends in Microbiology 2003, 11:431-437.
20. Chen C., Fu Z., Kim J.J., Barbieri J.T., Baldwin M.R. Gangliosides as high affinity receptors for tetanus neurotoxin. Journal of Biological Chemistry 2009, 284:26569-26577.
21. Herreros J., Lalli G., Montecucco C., Schiavo G. Tetanus toxin fragment C binds to a protein present in neuronal cell lines and motoneurons. Journal of Neurochemistry 2000, 74:1941-1950.
22. Dolly J.O., O'Connell M.A. Neurotherapeutics to inhibit exocytosis from sensory neurons for the control of chronic pain. Current Opinion in Pharmacology 2012, 12:100-108.
23. Chaddock J.A., Herbert M.H., Ling R.J., Alexander F.C., Fooks S.J., Revell D.F., Quinn C.P., Shone C.C., Foster K.A. Expression and purification of catalytically active, non-toxic endopeptidase derivatives of Clostridium botulinum toxin type A. Protein Expression and Purification 2002, 25:219-228.
24. Moriishi K., Koura M., Abe N., Fujii N., Fujinaga Y., Inoue K., Ogumad K. Mosaic structures of neurotoxins produced from Clostridium botulinum types C and D organisms. Biochimica et Biophysica Acta 1996, 1307:123-126.
25. Kroken A.R., Karalewitz A.P., Fu Z., Baldwin M.R., Kim J.J., Barbieri J.T. Unique ganglioside binding by botulinum neurotoxins C and D-SA. FEBS Journal 2011, 278:4486-4496.
26. Nakamura K., Kohda T., Umeda K., Yamamoto H., Mukamoto M., Kozaki S. Characterization of the D/C mosaic neurotoxin produced by Clostridium botulinum associated with bovine botulism in Japan. Veterinary Microbiology 2010, 140:147-154.
27. Chaddock J.A., Purkiss J.R., Duggan M.J., Quinn C.P., Shone C.C., Foster K.A. A conjugate composed of nerve growth factor coupled to a non-toxic derivative of Clostridium botulinum neurotoxin type A can inhibit neurotransmitter release in vitro. Growth Factors 2000, 18:147-155.
28. Chaddock J.A., Purkiss J.R., Friis L.M., Broadbridge J.D., Duggan M.J., Fooks S.J., Shone C.C., Quinn C.P., Foster K.A. Inhibition of vesicular secretion in both neuronal and nonneuronal cells by a retargeted endopeptidase derivative of Clostridium botulinum neurotoxin type A. Infection and Immunity 2000, 68:2587-2593.
29. Duggan M.J., Quinn C.P., Chaddock J.A., Purkiss J.R., Alexander F.C., Doward S., Fooks S.J., Friis L.M., Hall Y.H., Kirby E.R., Leeds N., Moulsdale H.J., Dickenson A., Green G.M., Rahman W., Suzuki R., Shone C.C., Foster K.A. Inhibition of release of neurotransmitters from rat dorsal root ganglia by a novel conjugate of a Clostridium botulinum toxin A endopeptidase fragment and Erythrina cristagalli lectin. Journal of Biological Chemistry 2002, 277:34846-34852.
30. Caleo M., Schiavo G. Central effects of tetanus and botulinum neurotoxins. Toxicon 2009, 54:593-599.
31. Pellett S., Tepp W.H., Stanker L.H., Band P.A., Johnson E.A., Ichtchenko K. Neuronal targeting, internalization, and biological activity of a recombinant atoxic derivative of botulinum neurotoxin A. Biochemical and Biophysical Research Communications 2011, 405:673-677.
32. Bade S., Rummel A., Reisinger C., Karnath T., Ahnert-Hilger G., Bigalke H., Binz T. Botulinum neurotoxin type D enables cytosolic delivery of enzymatically active cargo proteins to neurones via unfolded translocation intermediates. Journal of Neurochemistry 2004, 91:1461-1472.
33. O'Leary V.B., Ovsepian S.V., Raghunath A., Huo Q., Lawrence G.W., Smith L., Dolly J.O. Innocuous full-length botulinum neurotoxin targets and promotes the expression of lentiviral vectors in central and autonomic neurons. Gene Therapy 2011, 18:656-665.
34. Darios F., Niranjan D., Ferrari E., Zhang F., Soloviev M., Rummel A., Bigalke H., Suckling J., Ushkaryov Y., Naumenko N., Shakirzyanova A., Giniatullin R., Maywood E., Hastings M., Binz T., Davletov B. SNARE tagging allows stepwise assembly of a multimodular medicinal toxin. Proceedings of the National Academy of Sciences of the United States of America 2010, 107:18197-18201.
35. Ferrari E., Maywood E.S., Restani L., Caleo M., Pirazzini M., Rossetto O., Hastings M.H., Niranjan D., Schiavo G., Davletov B. Re-assembled botulinum neurotoxin inhibits CNS functions without systemic toxicity. Toxins (Basel) 2011, 3:345-355.
36. Ferrari E., Soloviev M., Niranjan D., Arsenault J., Gu C., Vallis Y., O'Brien J., Davletov B. Assembly of protein building blocks using a short synthetic peptide. Bioconjugate Chemistry 2012, 23:479-484.
37. Rummel A., Mahrhold S., Bigalke H., Binz T. Exchange of the H(CC) domain mediating double receptor recognition improves the pharmacodynamic properties of botulinum neurotoxin. FEBS Journal 2011, 278:4506-4515.
38. Chen S., Barbieri J.T. Engineering botulinum neurotoxin to extend therapeutic intervention. Proceedings of the National Academy of Sciences of the United States of America 2009, 106:9180-9184.
39. Jankovic J. Disease-oriented approach to botulinum toxin use. Toxicon: Official Journal of the International Society on Toxinology 2009, 54:614-623.
40. Bajohrs M., Rickman C., Binz T., Davletov B. A molecular basis underlying differences in the toxicity of botulinum serotypes A and E. EMBO Reports 2004, 5:1090-1095.
41. Zhao L.C., Yang B., Wang R., Lipton S.A., Zhang D. Type C botulinum toxin causes degeneration of motoneurons in vivo. Neuroreport 2010, 21:14-18.
42. Longenecker H.E., Hurlbut W.P., Mauro A., Clark A.W. Effects of black widow spider venom on the frog neuromuscular junction. Effects on end-plate potential, miniature end-plate potential and nerve terminal spike. Nature 1970, 225:701-703.
43. 2+. Proceedings of the National Academy of Sciences of the United States of America 1979, 76:991-995.
44. 2+-dependent recycling of synaptic vesicles at the frog neuromuscular junction. Journal of Cell Biology 1980, 87:297-303.
45. Tsang C.W., Elrick D.B., Charlton M.P. Alpha-latrotoxin releases calcium in frog motor nerve terminals. Journal of Neuroscience 2000, 20:8685-8692.
46. Capogna M., Gahwiler B.H., Thompson S.M. Calcium-independent actions of alpha-latrotoxin on spontaneous and evoked synaptic transmission in the hippocampus. Journal of Neurophysiology 1996, 76:3149-3158.
47. 2+ on quantal secretion at the frog neuromuscular junction. Journal of General Physiology 1986, 88:59-81.
48. Auger C., Marty A. Heterogeneity of functional synaptic parameters among single release sites. Neuron 1997, 19:139-150.
49. Silva J.P., Lelianova V., Hopkins C., Volynski K.E., Ushkaryov Y. Functional cross-interaction of the fragments produced by the cleavage of distinct adhesion G-protein-coupled receptors. Journal of Biological Chemistry 2009, 284:6495-6506.
50. Castillo J.D., Pumplin D.W. Discrete and discontinuous action of brown widow spider venom on the presynaptic nerve terminals of frog muscle. Journal of Physiology 1975, 252:491-508.
51. Lelyanova V.G., Thomson D., Ribchester R.R., Tonevitsky E.A., Ushkaryov Y.A. Activation of alpha-latrotoxin receptors in neuromuscular synapses leads to a prolonged splash acetylcholine release. Bulletin of Experimental Biology and Medicine 2009, 147:701-703.
52. Lelianova V.G., Davletov B.A., Sterling A., Rahman M.A., Grishin E.V., Totty N.F., Ushkaryov Y.A. Alpha-latrotoxin receptor, latrophilin, is a novel member of the secretin family of G protein-coupled receptors. Journal of Biological Chemistry 1997, 272:21504-21508.
53. 2+ and is mediated by latrophilin, G proteins and phospholipase C. Philosophical Transactions of the Royal Society of London, Series B: Biological Sciences 1999, 354:379-386.
54. 2+. EMBO Journal 1998, 17:3909-3920.
55. 2+-dependent pathways, triggers exocytosis of two pools of synaptic vesicles. Journal of Biological Chemistry 2001, 276:44695-44703.
56. Volynski K.E., Silva J.P., Lelianova V.G., Atiqur Rahman M., Hopkins C., Ushkaryov Y.A. Latrophilin fragments behave as independent proteins that associate and signal on binding of LTX(N4C). EMBO Journal 2004, 23:4423-4433.
57. Vicentini L.M., Meldolesi J. Alpha latrotoxin of black widow spider venom binds to a specific receptor coupled to phosphoinositide breakdown in PC12 cells. Biochemical and Biophysical Research Communications 1984, 121:538-544.
58. Capogna M., Volynski K.E., Emptage N.J., Ushkaryov Y.A. The alpha-latrotoxin mutant LTXN4C enhances spontaneous and evoked transmitter release in CA3 pyramidal neurons. Journal of Neuroscience 2003, 23:4044-4053.
59. Khvotchev M., Lonart G., Sudhof T.C. Role of calcium in neurotransmitter release evoked by alpha-latrotoxin or hypertonic sucrose. Neuroscience 2000, 101:793-802.
60. Matteoli M., Haimann C., Torri-Tarelli F., Polak J.M., Ceccarelli B., De Camilli P. Differential effect of alpha-latrotoxin on exocytosis from small synaptic vesicles and from large dense-core vesicles containing calcitonin gene-related peptide at the frog neuromuscular junction. Proceedings of the National Academy of Sciences of the United States of America 1988, 85:7366-7370.
61. Grasso A., Alema S., Rufini S., Senni M.I. Black widow spider toxin-induced calcium fluxes and transmitter release in a neurosecretory cell line. Nature 1980, 283:774-776.
62. i. Journal of Physiology 1997, 502(Pt 3):481-496.
63. Silva A.M., Liu-Gentry J., Dickey A.S., Barnett D.W., Misler S. Alpha-latrotoxin increases spontaneous and depolarization-evoked exocytosis from pancreatic islet beta-cells. Journal of Physiology 2005, 565:783-799.
64. Meldolesi J., Madeddu L., Torda M., Gatti G., Niutta E. The effect of alpha-latrotoxin on the neurosecretory PC12 cell line: studies on toxin binding and stimulation of transmitter release. Neuroscience 1983, 10:997-1009.
65. 2+-independent insulin exocytosis induced by alpha-latrotoxin requires latrophilin, a G protein-coupled receptor. EMBO Journal 1998, 17:648-657.
66. Tse F.W., Tse A. Alpha-latrotoxin stimulates inward current, rise in cytosolic calcium concentration, and exocytosis in at pituitary gonadotropes. Endocrinology 1999, 140:3025-3033.
67. Sudhof T.C. Alpha-latrotoxin and its receptors: neurexins and CIRL/latrophilins. Annual Review of Neuroscience 2001, 24:933-962.
68. Kiyatkin N.I., Kulikovskaya I.M., Grishin E.V., Beadle D.J., King L.A. Functional characterization of black widow spider neurotoxins synthesised in insect cells. European Journal of Biochemistry 1995, 230:854-859.
69. Sedgwick S.G., Smerdon S.J. The ankyrin repeat: a diversity of interactions on a common structural framework. Trends in Biochemical Sciences 1999, 24:311-316.
70. Orlova E.V., Rahman M.A., Gowen B., Volynski K.E., Ashton A.C., Manser C., van Heel M., Ushkaryov Y.A. Structure of alpha-latrotoxin oligomers reveals that divalent cation-dependent tetramers form membrane pores. Natural Structural Biology 2000, 7:48-53.
71. Ashton A.C., Rahman M.A., Volynski K.E., Manser C., Orlova E.V., Matsushita H., Davletov B.A., van Heel M., Grishin E.V., Ushkaryov Y.A. Tetramerisation of alpha-latrotoxin by divalent cations is responsible for toxin-induced non-vesicular release and contributes to the Ca(2+)-dependent vesicular exocytosis from synaptosomes. Biochimie 2000, 82:453-468.
72. Ichtchenko K., Khvotchev M., Kiyatkin N., Simpson L., Sugita S., Sudhof T.C. Alpha-latrotoxin action probed with recombinant toxin: receptors recruit alpha-latrotoxin but do not transduce an exocytotic signal. EMBO Journal 1998, 17:6188-6199.
73. Tzeng M.C., Cohen R.S., Siekevitz P. Release of neurotransmitters and depletion of synaptic vesicles in cerebral cortex slices by alpha-latrotoxin from black widow spider venom. Proceedings of the National Academy of Sciences of the United States of America 1978, 75:4016-4020.
74. Grishin E.V. Black widow spider toxins: the present and the future. Toxicon 1998, 36:1693-1701.
75. Rohou A., Nield J., Ushkaryov Y.A. Insecticidal toxins from black widow spider venom. Toxicon 2007, 49:531-549.
76. Dulubova I.E., Krasnoperov V.G., Khvotchev M.V., Pluzhnikov K.A., Volkova T.M., Grishin E.V., Vais H., Bell D.R., Usherwood P.N. Cloning and structure of delta-latroinsectotoxin, a novel insect-specific member of the latrotoxin family: functional expression requires C-terminal truncation. Journal of Biological Chemistry 1996, 271:7535-7543.
77. Frontali N., Ceccarelli B., Gorio A., Mauro A., Siekevitz P., Tzeng M.C., Hurlbut W.P. Purification from black widow spider venom of a protein factor causing the depletion of synaptic vesicles at neuromuscular junctions. Journal of Cell Biology 1976, 68:462-479.
78. Magazanik L.G., Fedorova I.M., Kovalevskaya G.I., Pashkov V.N., Bulgakov O.V., Grishin E.V. Selective presynaptic insectotoxin (alpha-latroinsectotoxin) isolated from black widow spider venom. Neuroscience 1992, 46:181-188.
79. Mee C.J., Tomlinson S.R., Perestenko P.V., De Pomerai D., Duce I.R., Usherwood P.N., Bell D.R. Latrophilin is required for toxicity of black widow spider venom in Caenorhabditis elegans. Biochemical Journal 2004, 378:185-191.
80. Willson J., Amliwala K., Davis A., Cook A., Cuttle M.F., Kriek N., Hopper N.A., O'Connor V., Harder A., Walker R.J., Holden-Dye L. Latrotoxin receptor signaling engages the UNC-13-dependent vesicle-priming pathway in C. elegans. Current Biology 2004, 14:1374-1379.
81. Volynski K.E., Nosyreva E.D., Ushkaryov Y.A., Grishin E.V. Functional expression of alpha-latrotoxin in baculovirus system. FEBS Letters 1999, 442:25-28.
82. 2+-dependent exocytosis. Journal of Neuroscience 2005, 25:10188-10197.
83. Volynski K.E., Capogna M., Ashton A.C., Thomson D., Orlova E.V., Manser C.F., Ribchester R.R., Ushkaryov Y.A. Mutant alpha-latrotoxin (LTXN4C) does not form pores and causes secretion by receptor stimulation: this action does not require neurexins. Journal of Biological Chemistry 2003, 278:31058-31066.
84. 2+-dependent synaptic exocytosis independent of the classical synaptic fusion machinery. Journal of Neuroscience 2009, 29:8639-8648.
85. Liu J., Wan Q., Lin X., Zhu H., Volynski K., Ushkaryov Y., Xu T. Alpha-latrotoxin modulates the secretory machinery via receptor-mediated activation of protein kinase C. Traffic 2005, 6:756-765.
86. 2+ channels via latrophilin in beta-cells. Journal of Biological Chemistry 2006, 281:5522-5531.